Discontinuing Intuniv (Guanfacine ER) in a 12-Year-Old on 4mg Daily
Taper the dose by no more than 1 mg every 3 to 7 days to minimize rebound hypertension. For a patient on 4 mg daily, this means reducing to 3 mg for 3-7 days, then 2 mg for 3-7 days, then 1 mg for 3-7 days before complete discontinuation 1.
Recommended Tapering Schedule
The FDA-approved prescribing information provides explicit guidance on discontinuation 1:
- Week 1: Reduce from 4 mg to 3 mg daily
- Week 2: Reduce from 3 mg to 2 mg daily
- Week 3: Reduce from 2 mg to 1 mg daily
- Week 4: Discontinue completely
This schedule uses 7-day intervals at each dose reduction, which represents the more conservative end of the recommended range and is appropriate for a patient on the maximum studied dose.
Critical Safety Considerations
Rebound hypertension is the primary concern when discontinuing guanfacine. The 2019 AAP ADHD guidelines specifically warn that "rebound hypertension after abrupt guanfacine and clonidine discontinuation has been observed" and emphasize that "these medications should be tapered off rather than suddenly discontinued" 2.
Why Tapering Matters
- Guanfacine is an alpha-2A adrenergic agonist that lowers blood pressure and heart rate during treatment
- Abrupt discontinuation can cause transient blood pressure elevations above baseline
- While research in young adults showed minimal rebound with abrupt cessation 3, the FDA label and clinical guidelines prioritize the safer tapering approach, particularly in pediatric patients
- Studies in adults with hypertension demonstrated gradual blood pressure recovery over 2-4 days with withdrawal 4, 5
Monitoring During Discontinuation
Monitor blood pressure and heart rate at each dose reduction and for 1-2 weeks after complete discontinuation. Watch specifically for:
- Blood pressure elevation above the patient's pre-treatment baseline
- Symptoms of rebound hypertension: headache, nervousness, agitation
- Return of ADHD symptoms (may occur within days to weeks)
- Irritability or mood changes
The general medication discontinuation guideline emphasizes that "a thoughtful and safe plan for medication discontinuation is as important as a thoughtful and safe plan for starting medications" 6.
Special Circumstances
If the patient misses 2 or more consecutive doses, do not resume at 4 mg. The FDA label advises that physicians should "consider titration based on patient tolerability" when reinitiating after missed doses 1. This same principle applies if you need to pause the taper.
Faster tapering (every 3 days instead of 7 days) may be considered if:
- The patient has been on guanfacine for a short duration (< 3 months)
- Close monitoring is feasible
- No cardiovascular risk factors are present
However, the 7-day interval remains the safer default approach for a 12-year-old on the maximum dose.
Common Pitfalls to Avoid
- Never stop abruptly – even though one study showed minimal rebound in healthy young adults 3, clinical guidelines and FDA labeling prioritize gradual tapering for patient safety
- Don't assume ADHD symptoms will return immediately – inattentive symptoms may take longer to manifest than hyperactive symptoms, requiring extended monitoring 6
- Don't forget baseline blood pressure – you need the pre-treatment baseline to identify true rebound hypertension versus return to baseline